
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    ### **Step-by-Step Analysis of the Provided Marker List** #### **1. List the Key Functional Markers** The following genes are associated with immune cell function, particularly cytotoxicity and immune regulation: - **Cytotoxic Effector Molecules:** - *GZMA, GZMB, GZMH, GZMK, GZMM* (Granzymes, involved in target cell killing) - *PRF1* (Perforin, pore-forming protein for cytotoxicity) - *IFNG* (Interferon-gamma, pro-inflammatory cytokine) - *CCL4, CCL4L2, CCL5* (Chemokines involved in immune cell recruitment) - **NK and T Cell Activation/Inhibition Markers:** - *KLRK1 (NKG2D), KLRC2 (NKG2C), KLRC4 (NKG2A), KLRD1 (CD94)* (NK cell receptors) - *TIGIT, LAG3, CD160* (Immune checkpoint inhibitors) - *TNFRSF9 (4-1BB), TMIGD2 (CD28H)* (Co-stimulatory molecules) - **T Cell/NK Cell Lineage Markers:** - *CD8A, CD8B* (CD8+ T cell markers) - *NKG7* (NK and cytotoxic T cell marker) - *CD7* (Pan-T cell marker) #### **2. List the Key Cell Type Markers** The following genes strongly suggest an **immune cell type**, specifically **cytotoxic lymphocytes**: - **NK Cell Markers:** - *KLRD1 (CD94), KLRC2 (NKG2C), KLRK1 (NKG2D), KLRC4 (NKG2A)* (NK cell receptors) - *XCL1, XCL2* (Chemokines secreted by NK cells) - **Cytotoxic T Cell Markers:** - *CD8A, CD8B* (CD8+ T cell markers) - *GZMA, GZMB, PRF1* (Cytotoxic effector molecules) - *TRGC1, TRGC2* (Gamma-delta T cell receptors) - **Shared NK/T Cell Markers:** - *NKG7, CST7, CTSW* (Common in NK and cytotoxic T cells) #### **3. Cross-reference Known Databases** - **Human Cell Atlas (HCA), Azimuth, CellMarkerDB, and PanglaoDB** confirm that: - *KLRC2, KLRD1, KLRK1, XCL1, XCL2* are enriched in **NK cells**. - *CD8A, CD8B, GZMB, PRF1* are enriched in **CD8+ cytotoxic T cells**. - *TRGC1, TRGC2* suggest a **gamma-delta (Œ≥Œ¥) T cell** subset. #### **4. Determine the Most Probable General Cell Type** The **strongest signal** comes from **cytotoxic lymphocytes**, with a mix of **NK cell and CD8+ T cell markers**. Given the co-expression of *NKG7, GZMs, PRF1, CD8A/B*, and *KLR family genes*, the most likely **general cell type** is: **Cytotoxic Lymphocytes (NK cells or CD8+ T cells)** #### **5. Identify the Top 3 Most Probable Sub Cell Types** Ranked by likelihood: 1. **CD8+ Cytotoxic T Cells (Tissue-resident memory or effector T cells)** - Evidence: *CD8A, CD8B, GZMA/B/H/K/M, PRF1, IFNG, CCL4/5* - *TRGC1/TRGC2* may indicate a **Œ≥Œ¥ T cell subset**, but *CD8A/B* is more dominant. 2. **Natural Killer (NK) Cells (Tissue-resident NK cells)** - Evidence: *KLRC2, KLRD1, KLRK1, XCL1, XCL2, NKG7* - However, *CD8A/B* is atypical for NK cells, suggesting a minor contribution. 3. **Gamma-Delta (Œ≥Œ¥) T Cells** - Evidence: *TRGC1, TRGC2, GZMs, PRF1* - But *CD8A/B* is not typical for Œ≥Œ¥ T cells, making this less likely. **Final Subtype Decision:** The **strongest evidence** supports **CD8+ cytotoxic T cells**, likely **effector memory or tissue-resident memory (Trm) CD8+ T cells**, given the high expression of cytotoxic molecules (*GZMs, PRF1*) and chemokines (*CCL4, CCL5*). #### **6. Concise Summary of Analysis** - **Key Functional Markers:** Cytotoxic effectors (*GZMs, PRF1, IFNG*), NK/T cell receptors (*KLR family*), and chemokines (*CCL4/5, XCL1/2*). - **Key Cell Type Markers:** *CD8A/B* (T cells), *KLRC2/KLRD1* (NK cells), *TRGC1/2* (Œ≥Œ¥ T cells). - **Cross-referencing:** Databases confirm **cytotoxic T/NK cell identity**. - **General Cell Type:** **Cytotoxic Lymphocytes (CD8+ T cells most likely)**. - **Top 3 Subtypes:** 1. **CD8+ Cytotoxic T Cells (Effector/Memory)** 2. **NK Cells** 3. **Œ≥Œ¥ T Cells** - **Final Annotation:** **CD8+ Cytotoxic T Cells (Tissue-resident or Effector Memory Phenotype)** **FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    ### **Validation of Annotation: CD8+ Cytotoxic T Cells (Tissue-resident or Effector Memory Phenotype)** #### **1. Marker Consistency Check** The proposed annotation is **CD8+ Cytotoxic T Cells**, supported by the following markers in the provided list: - **CD8+ T Cell Markers:** - *CD8A, CD8B* (Core CD8+ T cell markers) - *GZMA, GZMB, GZMH, GZMK, GZMM* (Cytotoxic granzymes) - *PRF1* (Perforin, cytotoxic function) - *IFNG* (Effector cytokine) - *CCL4, CCL4L2, CCL5* (Chemokines for immune recruitment) - **T Cell Activation/Exhaustion Markers:** - *TIGIT, LAG3, CD160* (Checkpoint inhibitors) - *TNFRSF9 (4-1BB)* (Co-stimulatory molecule) - **Shared NK/T Cell Markers:** - *NKG7, CST7, CTSW* (Common in cytotoxic lymphocytes) **Conclusion:** The markers strongly support a **cytotoxic CD8+ T cell identity**, with no major inconsistencies. #### **2. Mixed Cell Type Consideration** The dataset also includes some **NK cell-associated markers**: - *KLRC2 (NKG2C), KLRD1 (CD94), KLRK1 (NKG2D), XCL1, XCL2* However: - The **dominant signal** comes from **CD8+ T cell markers** (*CD8A/B, GZMs, PRF1*). - NK cell markers (*KLRC2, KLRD1, XCL1/2*) could indicate: - A minor **NK cell contamination** (unlikely to be dominant). - **CD8+ T cells with NK-like features** (e.g., tissue-resident memory T cells expressing NK receptors). **Conclusion:** The **primary annotation (CD8+ T cells) is valid**, but the presence of NK markers suggests either: - A **minor NK cell subpopulation** (if clustering resolution allows, consider subclustering). - **Hybrid cytotoxic T cells with NK-like properties** (common in tissue-resident subsets). #### **3. Final Validation Decision** - **VALIDATION PASSED** (Primary annotation is correct). - **Recommendation:** - If further resolution is possible, check for **NK cell contamination** (e.g., recluster using *KLRC2, XCL1* vs. *CD8A/B*). - Alternatively, refine the annotation to: - **'CD8+ Cytotoxic T Cells (NK-like or Tissue-resident Memory Phenotype)'** to account for NK marker expression. **Validation result: VALIDATION PASSED** **Feedback:** The annotation is well-supported, but consider refining the label to reflect potential NK-like features or verifying subclustering for purity.
                </div>
            
                    <div class="agent-section formatting">
                        <h2>üìã Summary</h2>
                        <p class="error-message">Error formatting data: Expecting property name enclosed in double quotes: line 1 column 3 (char 2)</p>
                    </div>
                
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">95</div>
                        <div class="scoring-content">
                            The annotation results demonstrate a strong and scientifically accurate analysis of the provided marker list, with several notable strengths:<br><br>1. **Correctness of Annotations**: The primary annotation as **CD8+ Cytotoxic T Cells (Tissue-resident or Effector Memory Phenotype)** is well-supported by the majority of markers, including *CD8A/B*, *GZMA/B/H/K/M*, *PRF1*, and *IFNG*. The inclusion of NK cell markers (*KLRC2, KLRD1, XCL1/2*) is appropriately addressed, with the explanation that these could indicate either minor NK cell contamination or NK-like features in CD8+ T cells, which is a reasonable interpretation.<br><br>2. **Balanced Consideration of Markers**: The analysis does not overemphasize any single marker but instead integrates multiple lines of evidence. For example, it considers both cytotoxic effectors (*GZMs, PRF1*) and immune checkpoint molecules (*TIGIT, LAG3*), providing a holistic view of the cell type's functional state.<br><br>3. **Comprehensive View of Cell Types**: The annotation captures the complexity of the data by acknowledging potential subpopulations (e.g., Œ≥Œ¥ T cells) and mixed signals (NK-like features). The ranking of sub-cell types (CD8+ T cells > NK cells > Œ≥Œ¥ T cells) reflects the relative strength of the marker evidence.<br><br>4. **Cross-Referencing with Databases**: The use of external databases (HCA, Azimuth, etc.) to validate markers adds credibility to the annotations.<br><br>5. **Ranking of Markers**: The analysis implicitly considers marker importance by prioritizing *CD8A/B* and cytotoxic molecules over less specific markers (e.g., *TRGC1/2* for Œ≥Œ¥ T cells).<br><br>**Weaknesses/Improvements**:<br>- The annotation could be slightly refined to explicitly label the population as **CD8+ Cytotoxic T Cells with NK-like Features** to better reflect the dual expression pattern.<br>- While the analysis mentions Œ≥Œ¥ T cells, it correctly downplays their likelihood due to the dominance of *CD8A/B*. However, a brief explanation of why *TRGC1/2* alone is insufficient for Œ≥Œ¥ T cell annotation would strengthen the reasoning.<br><br>**Overall**, the annotation is robust, accurate, and comprehensive, with only minor room for refinement.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    